Skip to content
Open access

The missing improvers: Tau pathology, neuroplasticity, and the case for tau-informed patient selection before amyloid immunotherapy

Aug 2026 · The journal of prevention of Alzheimer's disease · Vol 13, pp. 100653 · 0 citations · 19 references
Medicine

TL;DR

It is proposed that tau status should be given strong consideration in patient selection, that tau-guided selection should be evaluated prospectively, and that the access, reimbursement, and standardization barriers to tau positron emission tomography (PET) — together with the promise of scalable plasma tau biomarkers — be addressed deliberately as the field moves toward tau-informed treatment.

Abstract

Amyloid immunotherapy with lecanemab and donanemab has been approved on the basis of statistically significant slowing of cognitive and functional decline in early Alzheimer's disease (1,2). Yet clinicians treating individual patients face the everyday challenge of estimating whether a given patient is declining at the rate that would be expected for them, and whether their trajectory reflects a response to treatment. I argue that this difficulty arises in large part because the field cannot yet routinely stratify patients by tau pathology before treatment, even though tau burden is among the strongest available predictors of both the rate of progression and the magnitude of response to amyloid-targeting therapy. Post-hoc and open-label analyses of the Clarity AD and TRAILBLAZER-ALZ 2 programmes suggest that patients with absent, low, or medium tau burden may constitute a biologically distinct group in whom amyloid clearance is most likely to permit clinical stabilization or measurable functional gain. These observations remain hypotheses, generated largely from subgroup, open-label, and biomarker data rather than from prospective trials designed to test them I propose that tau status should be given strong consideration in patient selection, that tau-guided selection should be evaluated prospectively, and that the access, reimbursement, and standardization barriers to tau positron emission tomography (PET) — together with the promise of scalable plasma tau biomarkers — be addressed deliberately as the field moves toward tau-informed treatment. One tau PET tracer is currently approved by the US Food and Drug Administration, and a regulatory decision on a second is anticipated in 2026.

Read PDF

Similar papers

Review Open access Sep 2026

Rethinking tau‐targeted therapy in Alzheimer's disease: Toward a dual biomarker strategy

A dual‐domain framework is proposed in which tau‐targeted therapies are evaluated using complementary measures of aggregated tau burden and biologically defined soluble tau states, and treatment‐induced increases should be considered favorable only when they accompany aggregate reduction and evidence of a less pathogen...

C. Teunissen, L. Pini, B. Imbimbo · 0 citations
Review Open access Sep 2026

Alzheimer’s Disease in the Era of Geroscience: Mechanisms, Biomarkers, and Therapeutic Prospects

This narrative review examines AD mechanisms, biomarkers, and therapeutic prospects from a geroscience perspective and applies the eight hallmarks of neurodegenerative diseases as an analytical framework to establish which preventive strategies and biomarker-guided, stage-matched combination therapies improve clinicall...

P. Chmielewski · 0 citations
Review Open access Oct 2026

Cognitive Reserve: White Matter, Microvascular, Glymphatic and Cholinergic Dysfunction in Alzheimer’s Disease

Late-onset Alzheimer’s disease (LOAD) is a cognitive disorder that leads to the requirement of full-time care. The ever-increasing growth of the LOAD population demands that more research be dedicated to the discovery/design of effective therapeutics. The two major hypotheses that have been evaluated in the clinic incl...

Paul L. Wood · 0 citations
Review Sep 2026

Atypical Alzheimer disease: a multi-axis framework toward defining heterogeneity.

A practical multi-axis framework comprising clinical phenotype, AD biological context (AD pathology plus co-pathologies and molecular modifiers), network topography (regional patterns) and tempo (rate of clinical and biomarker progression) is proposed to reduce diagnostic mismatches, make cohorts more comparable and su...

L. Grinberg, M. Murray · 0 citations
Open access Aug 2026

Real-world anti-amyloid therapy beyond traditional symptomatic populations: a longitudinal case series

Introduction Anti-amyloid monoclonal antibodies are approved as disease-modifying therapies for early Alzheimer’s disease (AD), but real-world evidence remains limited, particularly among individuals treated during preclinical or minimally symptomatic stages. This study characterized clinical and biomarker trajectories...

Jayoung Han, Yuan Fang, Darlingtina K. Esiaka et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.